✦ LIBER ✦

A randomized trial of preemptive therapy for prevention of cytomegalovirus disease after allogeneic hematopoietic stem cell transplantation

✍ Scribed by Seung Tae Kim; Mark H. Lee; Sung Yong Kim; Seok Jin Kim; Dong Hwan Kim; Jun Ho Jang; Kihyun Kim; Won Seog Kim; Chul Won Jung

Publisher: Carden Jennings Publishing
Year: 2010
Tongue: English
Weight: 207 KB
Volume: 91
Category: Article
ISSN: 0925-5710
DOI: 10.1007/s12185-010-0580-2

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Risk-Adapted Preemptive Therapy for Cyto

Risk-Adapted Preemptive Therapy for Cytomegalovirus Disease after Allogeneic Stem Cell Transplantation: A Single-Center Experience in Korea

✍ Su-Mi Choi; Dong-Gun Lee; Jung-Hyun Choi; Jin-Hong Yoo; Yoo-Jin Kim; Sun Hee Par 📂 Article 📅 2006 🏛 Carden Jennings Publishing 🌐 English ⚖ 42 KB

Use of foscarnet for cytomegalovirus inf

Use of foscarnet for cytomegalovirus infection after allogeneic hematopoietic stem cell transplantation from a related donor

✍ Maiko Asakura; Kazuhiro Ikegame; Satoshi Yoshihara; Shuichi Taniguchi; Takehiko 📂 Article 📅 2010 🏛 Carden Jennings Publishing 🌐 English ⚖ 605 KB

Second Allogeneic Hematopoietic Stem Cel

Second Allogeneic Hematopoietic Stem Cell Transplantation for Leukemia Relapse After First Allogeneic Transplantation: Outcome of 16 Patients in a Single Institution

✍ Akira Tomonari; Tohru Iseki; Jun Ooi; Hitomi Nagayama; Hiroyuki Sato; Tsutomu Ta 📂 Article 📅 2002 🏛 Carden Jennings Publishing 🌐 English ⚖ 94 KB

Cytomegalovirus infection and disease af

Cytomegalovirus infection and disease after allogeneic hematopoietic stem cell transplantation: experience in a center with a high seroprevalence of both CMV and hepatitis B virus

✍ Yi-Chang Liu; Po-Liang Lu; Hui-Hua Hsiao; Chao-Sung Chang; Ta-Chih Liu; Wen-Chi 📂 Article 📅 2011 🏛 Springer 🌐 English ⚖ 175 KB

Randomized controlled trials of autologo

Randomized controlled trials of autologous hematopoietic stem cell transplantation for autoimmune diseases: The evolution from myeloablative to lymphoablative transplant regimens

✍ Richard K. Burt; Alberto Marmont; Yu Oyama; Shimon Slavin; Renate Arnold; Falk H 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 104 KB 👁 2 views

Clinically-based determination of safe D

Clinically-based determination of safe DNAemia cutoff levels for preemptive therapy or human cytomegalovirus infections in solid organ and hematopoietic stem cell transplant recipients

✍ Daniele Lilleri; Fausto Baldanti; Marta Gatti; Francesca Rovida; Luca Dossena; S 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 101 KB

## Abstract Transplantation Centers using human cytomegalovirus (HCMV) antigenemia‐based preemptive therapy will need to replace in the near future the antigenemia assay with a more standardized and automatable assay, such as a molecular assay quantifying HCMV DNA in blood (DNAemia). Thus, in view